Achieving a dose which is both clinically effective and tolerable to patients without generating significant toxicity associated with WT EGFR inhibition has therefore been a major challenge for the treatment of EGFR exon 20 insertion NSCLC to date. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.